Recursion Pharmaceuticals, Inc. (RXRX) company profile

Recursion is a clinical-stage biotechnology company that utilizes an artificial intelligence-native platform to discover and develop therapeutic candidates. The company's operating system combines high-throughput biological data generation, computational small molecule design, and clinical development tools to address high unmet medical needs. Recursion advances an internal pipeline focused on rare diseases and oncology, including clinical-stage programs for familial adenomatous polyposis and advanced solid tumors. Additionally, it collaborates with large biopharmaceutical partners to discover novel targets and small molecule programs across neuroscience, oncology, and immunology.

The company operates automated high-throughput laboratories capable of conducting over two million experiments weekly, supported by proprietary supercomputing infrastructure. Its clinical-stage programs conduct patient enrollment across sites in the United States and Canada. Recursion also engages in multinational discovery and development partnerships with biopharmaceutical corporations based in countries such as Germany. While specific headquarters details are omitted from the text, the company's operational scale includes scaled dry labs, wet-lab facilities, and international clinical trial networks.

Summary of the business section of Recursion Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“The initial public offering price is $18.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“With a dedicated team of 50 people, Recursion set out to overcome numerous technical and biological challenges, all with the goal of driving innovation in neuroscience.”